Angiotensin converting enzyme inhibition in normotensive type II diabetics with persistent mild proteinuria.
To evaluate the effect of enalapril on proteinuria, 16 normotensive type II diabetics with persistent proteinuria were studied. At random, the patients were allocated to enalapril (5 mg once a day) or placebo, in a double-blind fashion, for 12 months. Blood pressure, heart rate, urinary albumin excretion, plasma renin activity and aldosterone, blood glucose, serum fructosamine, urine urea and body weight were checked monthly during the run-in period and every 2 months during the treatment period. The kidney function was studied at the beginning of the study and during the sixth and 12th months. Enalapril decreased urinary albumin excretion in our patients in the absence of any effect on blood pressure and kidney function. Our data may be interpreted on the basis of a direct vascular effect of enalapril that is probably related to a tissue mechanism consisting of reduced angiotensin formation, increased kinins, or both, or of other unknown factors.
Stornello
M
M
Centro per lo studio e la terapia dell'Ipertensione, Ospedale Generale Umberto l, Syracuse, Italy.
Valvo
E V
EV
Scapellato
L
L
D000419:Albuminuria / Q000188:drug therapy / Q000503:physiopathology / Q000652:urine; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology / Q000652:urine; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000503:physiopathology / Q000652:urine; D004311:Double-Blind Method; D004656:Enalapril / Q000627:therapeutic use*; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006801:Humans; D011507:Proteinuria / Q000188:drug therapy* / Q000503:physiopathology / Q000652:urine; D016032:Randomized Controlled Trials as Topic
D004656:Enalapril